Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. Reduced monthly costs for uninsured patients still amount to around ...

For CVS, Q2 earnings will be a critical inflection point. A miss could trigger a breakup or further decline, making the stock ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. Reduced monthly costs for uninsured patients still amount to around ...

A new survey reveals widespread consumer frustration with prior authorization, highlighting the need for urgent reform in ...

Recent health news highlights various developments, including Trump's spending bill impacting insurance costs, a major acquisition in the bioscience sector, and GSK's efforts to expand RSV vaccine ...

Rite Aid customers are now seeing the closure of more than 700 stores nationwide. Pennsylvania had 494 Rite Aids in 2022. The ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

From a CVS subsidiary ordered to pay nearly $950 million in a false claims case to the Supreme Court upholding the ACA’s preventive coverage mandate, here are 12 healthcare industry lawsuits, ...

Society / Forget Kennedy’s faux-populist, anti-science approach. The former FTC chair provides the real model of an ideal HHS ...

“EGT is opportunist. We’re looking for distressed assets that we can turn around,” he says. It’s a focus that’s served Raglan ...

Companies such as UnitedHealth, Centene and Humana are getting squeezed between rising costs and a stingier government.